Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANTE Study: De-escalation and Treatment-free Remission in CML Patients
NCT03874858Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2019
- Primary completion
- Oct 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib, asciminib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Mar 2019; status: terminated.
02
Drugs
nilotinibasciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03874858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03874858.